JP2012529281A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012529281A5 JP2012529281A5 JP2012514538A JP2012514538A JP2012529281A5 JP 2012529281 A5 JP2012529281 A5 JP 2012529281A5 JP 2012514538 A JP2012514538 A JP 2012514538A JP 2012514538 A JP2012514538 A JP 2012514538A JP 2012529281 A5 JP2012529281 A5 JP 2012529281A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- sequence
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 55
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 28
- 229940127121 immunoconjugate Drugs 0.000 claims 25
- 239000000203 mixture Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 12
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 9
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 9
- 241001465754 Metazoa Species 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000003384 imaging method Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 229940121819 ATPase inhibitor Drugs 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 claims 1
- 206010062038 Lip neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 206010029098 Neoplasm skin Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- -1 another antibody Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000000701 coagulant Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000006721 lip cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 210000001835 viscera Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18538709P | 2009-06-09 | 2009-06-09 | |
| GB0909904.5 | 2009-06-09 | ||
| US61/185,387 | 2009-06-09 | ||
| GBGB0909904.5A GB0909904D0 (en) | 2009-06-09 | 2009-06-09 | Product |
| PCT/GB2010/050969 WO2010142990A1 (en) | 2009-06-09 | 2010-06-09 | ANTI-EpCAM ANTIBODIES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012529281A JP2012529281A (ja) | 2012-11-22 |
| JP2012529281A5 true JP2012529281A5 (cg-RX-API-DMAC7.html) | 2013-07-25 |
Family
ID=40937119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012514538A Pending JP2012529281A (ja) | 2009-06-09 | 2010-06-09 | 抗ＥｐＣＡＭ抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8637017B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2440580A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2012529281A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102549017A (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI1011005A2 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201171463A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0909904D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010142990A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2382990B1 (en) | 2003-04-30 | 2014-09-17 | Universität Zürich | Methods for treating cancer using an immunotoxin |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| JP5687822B2 (ja) | 2006-10-12 | 2015-03-25 | 中外製薬株式会社 | 抗ｅｒｅｇ抗体を用いる癌の診断および治療 |
| US20120141501A1 (en) | 2009-05-29 | 2012-06-07 | Forerunner Pharma Research Co. Ltd | Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component |
| CN103561771B (zh) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
| JP6400470B2 (ja) | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| TWI593705B (zh) * | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
| EP2819695B1 (en) * | 2012-03-02 | 2018-06-27 | Academia Sinica | ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF |
| PL2897978T3 (pl) * | 2012-09-19 | 2017-08-31 | Abbvie Biotherapeutics Inc. | Sposoby identyfikacji przeciwciał o obniżonej immunogenności |
| CN103387990B (zh) * | 2012-09-24 | 2016-01-06 | 厦门大学 | 上皮细胞粘附分子的核酸适体EpCAM B及其制备方法 |
| US20140248292A1 (en) * | 2013-03-04 | 2014-09-04 | Oslo Universitetssykehus Hf | Compositions and methods for treating cancer |
| KR20150143458A (ko) * | 2013-03-06 | 2015-12-23 | 메리맥 파마슈티컬즈, 인크. | 항-C-MET 탠덤 Fc 이중특이적 항체 |
| EP2986324A4 (en) * | 2013-04-12 | 2016-12-14 | Viventia Bio Inc | COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA |
| CN103275226B (zh) * | 2013-06-09 | 2017-08-29 | 中国科学技术大学 | 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用 |
| CN105517571A (zh) * | 2013-06-24 | 2016-04-20 | 中外制药株式会社 | 含有人源化抗上皮调节蛋白抗体作为有效成分的腺癌以外的非小细胞肺癌的治疗药 |
| US9822182B2 (en) | 2013-10-02 | 2017-11-21 | Viventia Bio Inc. | Anti-EPCAM antibodies and methods of use |
| EP3268041A4 (en) | 2015-03-12 | 2018-09-05 | Viventia Bio Inc. | Dosing strategies for targeting epcam positive bladder cancer |
| CN108513547A (zh) | 2015-03-12 | 2018-09-07 | 维文蒂亚生物公司 | 用于epcam阳性膀胱癌的治疗方法 |
| WO2016161410A2 (en) | 2015-04-03 | 2016-10-06 | Xoma Technology Ltd. | Treatment of cancer using inhibitors of tgf-beta and pd-1 |
| EP3328897A1 (en) * | 2015-07-31 | 2018-06-06 | Sutro Biopharma, Inc. | ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EPCAM ANTIBODIES |
| AU2017233121B2 (en) | 2016-03-15 | 2023-12-21 | Itabmed (Hk) Limited | Multispecific Fab fusion proteins and use thereof |
| US20190262397A1 (en) | 2016-07-26 | 2019-08-29 | Tessa Therapeutics Pte. Ltd. | Chimeric antigen receptor |
| CN107814846A (zh) * | 2016-11-14 | 2018-03-20 | 杭州华得森生物技术有限公司 | 针对EpCAM和Cytokeratin5的特异性抗体及其制备方法 |
| WO2018178055A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| US20200277383A1 (en) * | 2017-09-07 | 2020-09-03 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| PT3749346T (pt) | 2018-02-08 | 2024-09-05 | Dragonfly Therapeutics Inc | Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d |
| KR20200118824A (ko) | 2018-02-08 | 2020-10-16 | 드래곤플라이 쎄라퓨틱스, 인크. | 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법 |
| CA3091424A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| CN108484771A (zh) * | 2018-04-24 | 2018-09-04 | 南京市妇幼保健院 | EpCAM单域抗体G7 |
| WO2019244973A1 (ja) | 2018-06-20 | 2019-12-26 | 中外製薬株式会社 | 標的細胞に対する免疫反応を活性化する方法およびその組成物 |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
| CA3108646A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| AU2019318083A1 (en) | 2018-08-08 | 2021-02-25 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| TWI897855B (zh) * | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| AU2019402097A1 (en) | 2018-12-17 | 2021-06-10 | Revitope Limited | Twin immune cell engager |
| CN113597432B (zh) * | 2019-04-22 | 2023-05-02 | 江苏恒瑞医药股份有限公司 | 抗EpCAM抗体及其应用 |
| CN110950959B (zh) * | 2020-02-25 | 2020-07-03 | 和铂医药(上海)有限责任公司 | 靶向EpCAM的抗体及其制备和应用 |
| CN111333730B (zh) * | 2020-03-11 | 2022-04-08 | 南京融捷康生物科技有限公司 | 可特异性结合EpCAM的单域抗体及其应用 |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| WO2021231237A2 (en) * | 2020-05-11 | 2021-11-18 | Augmenta Bioworks, Inc. | Antibodies for sars-cov-2 and uses thereof |
| CN112359052B (zh) * | 2020-08-20 | 2023-01-03 | 山东兴瑞生物科技有限公司 | 抗EpCAM嵌合抗原受体的编码基因、制备方法、具有该基因的质粒、免疫细胞及其应用 |
| TW202241967A (zh) * | 2021-01-11 | 2022-11-01 | 美商索特里亞生物治療藥物公司 | 基於茚地那韋的化學二聚化ｔ細胞銜接器組成物 |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| AR126009A1 (es) | 2021-06-02 | 2023-08-30 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam |
| CN113563474B (zh) * | 2021-06-11 | 2023-05-02 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | EpCAM-CD16-NKG2D三特异性抗体及其应用 |
| WO2024082269A1 (zh) * | 2022-10-21 | 2024-04-25 | 武汉友芝友生物制药股份有限公司 | 双特异性抗体在免疫细胞治疗方面的应用 |
| AU2024305352A1 (en) | 2023-06-12 | 2025-12-04 | Amgen Inc. | Lymphotoxin beta receptor agonist binding proteins |
| CN119409829B (zh) * | 2024-11-15 | 2025-08-22 | 康元医疗科技(大连)有限公司 | 抗EpCAM纳米抗体及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437213A1 (fr) | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
| WO1990010457A1 (en) | 1989-03-14 | 1990-09-20 | New York University | Method of treating hiv infections using immunotoxins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
| DE69332948T2 (de) | 1992-03-05 | 2003-11-27 | Board Of Regents, The University Of Texas System | Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US7227002B1 (en) | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
| US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
| GB9911569D0 (en) | 1999-05-18 | 1999-07-21 | Oxford Biomedica Ltd | Antibodies |
| ATE353920T1 (de) | 1999-12-27 | 2007-03-15 | Crucell Holland Bv | Menschlischer monoklonaler antikörper gegen ep- cam und dessen verwendung in krebstherapie |
| BR0209177A (pt) * | 2001-05-03 | 2004-10-05 | Merck Patent Gmbh | Anticorpo especìfico a tumor recombinante e uso do mesmo |
| DE10143106C1 (de) | 2001-09-03 | 2002-10-10 | Artus Ges Fuer Molekularbiolog | Vermehrung von Ribonukleinsäuren |
| CN1812999A (zh) * | 2003-05-31 | 2006-08-02 | 麦克罗梅特股份公司 | 包含EpCAM特异构建体的药物组合物 |
| WO2007042261A2 (en) * | 2005-10-11 | 2007-04-19 | Micromet Ag | Compositions comprising cross-species-specific antibodies and uses thereof |
| PT2142570E (pt) * | 2007-04-04 | 2011-09-13 | Sigma Tau Ind Farmaceuti | Anticorpos anti-epcam e suas utilizações |
| US8802442B2 (en) | 2011-11-30 | 2014-08-12 | Eric B. Wheeldon | Apparatus and method for the remote sensing of blood in human feces and urine |
-
2009
- 2009-06-09 GB GBGB0909904.5A patent/GB0909904D0/en not_active Ceased
-
2010
- 2010-06-09 EP EP10724121A patent/EP2440580A1/en not_active Withdrawn
- 2010-06-09 JP JP2012514538A patent/JP2012529281A/ja active Pending
- 2010-06-09 WO PCT/GB2010/050969 patent/WO2010142990A1/en not_active Ceased
- 2010-06-09 BR BRPI1011005A patent/BRPI1011005A2/pt not_active IP Right Cessation
- 2010-06-09 EA EA201171463A patent/EA201171463A1/ru unknown
- 2010-06-09 US US12/797,052 patent/US8637017B2/en not_active Expired - Fee Related
- 2010-06-09 CN CN2010800351667A patent/CN102549017A/zh active Pending